The Zhitong Finance App learned that Chunli Healthcare (01858) is now up more than 5%. As of press release, it has risen 5.18% to HK$12.18, with a turnover of HK$10.394 million.

According to the news, on April 30, the National Health Insurance Administration issued a continuous procurement document for artificial joint collection. Huachuang Securities believes that the price rules set in the No. 2 bid renewal document are more scientific and reasonable, the price expectations for joint products are stable, the certainty that the company will win the bid is higher, and the price difference between different companies is smaller. As joint collection continues to advance, the penetration rate and implantation volume of the joint market are expected to increase steadily, the concentration of the joint industry will further increase, and domestic substitution will continue to deepen, benefiting leading domestic companies.

Huatai Securities, on the other hand, believes that Chunli Medical's hip coverage is relatively good this time, accounting for the highest share of domestic companies; the gap between Tao-Tao/Tao-Chu, which has high hip coverage and the price of winning the bid in the previous round is limited; it is expected to contribute to the increase in performance after the company's knee renewal is successful. The bank said that external environmental factors affect short-term results, and it is optimistic that the 24-year performance will recover.